» Authors » Stefan Suciu

Stefan Suciu

Explore the profile of Stefan Suciu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 122
Citations 5362
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Musoro J, Sleurs C, Rowsell A, Suciu S, Kicinski M, Chantziara S, et al.
Pediatr Blood Cancer . 2024 Nov; 72(2):e31446. PMID: 39616416
Purpose: Survivors of childhood cancer can suffer from long-term sequelae or decline in quality of life (QoL), for which careful and standardized selection of outcome measures become more important. This...
2.
Domenech C, Kicinski M, De Moerloose B, Piette C, Chahla W, Kornreich L, et al.
Hemasphere . 2024 Nov; 8(11):e70025. PMID: 39540141
Here, we report the results of the prospective cohort study EORTC-CLG 58081 and compare them to the control arm of the randomized phase 3 trial EORTC-CLG 58951, on which treatment...
3.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
Eur J Cancer . 2024 Sep; 211:114327. PMID: 39288737
Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the...
4.
Efficace F, Kicinski M, Coens C, Suciu S, van der Velden W, Noppeney R, et al.
Blood . 2024 May; 144(5):541-551. PMID: 38717861
We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC)....
5.
Kennedy O, Glassee N, Kicinski M, Blank C, Long G, Atkinson V, et al.
Eur J Cancer . 2024 Feb; 201:113585. PMID: 38402687
Background: Pain is common in patients with cancer. The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate/severe pain....
6.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
NEJM Evid . 2024 Feb; 1(11):EVIDoa2200214. PMID: 38319852
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients...
7.
de Ville de Goyet M, Kicinski M, Suciu S, Vandecruys E, Uyttebroeck A, Ferster A, et al.
Discov Oncol . 2024 Jan; 15(1):20. PMID: 38285235
Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and...
8.
Baron F, Efficace F, Cannella L, Stevens-Kroef M, Amadori S, de Witte T, et al.
Am J Hematol . 2024 Jan; 99(3):486-489. PMID: 38174977
We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow...
9.
Lubbert M, Wijermans P, Kicinski M, Chantepie S, van der Velden W, Noppeney R, et al.
Lancet Haematol . 2023 Nov; 10(11):e879-e889. PMID: 37914482
Background: Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy...
10.
Kennedy O, Kicinski M, Valpione S, Gandini S, Suciu S, Blank C, et al.
Eur J Cancer . 2023 Jun; 189:112900. PMID: 37277264
Background: Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic...